April 3 (Reuters) - Pfizer Inc:
* SAYS CO AND ALLOGENE THERAPEUTICS ENTER INTO ASSET CONTRIBUTION AGREEMENT FOR PFIZER’S ALLOGENEIC CAR T IMMUNO-ONCOLOGY PORTFOLIO
* SAYS AGREEMENT AIMS TO ACCELERATE THE DEVELOPMENT OF PFIZER’S CAR T CELL THERAPY
* SAYS ALLOGENE WILL RECEIVE RIGHTS FROM CO TO 16 PRE-CLINICAL CAR T ASSETS LICENSED FROM CELLECTIS AND SERVIER
* SAYS ALLOGENE WILL RECEIVE RIGHTS TO ONE CLINICAL ASSET FROM SERVIER CALLED UCART19
* SAYS CO WILL HOLD 25 PERCENT STAKE IN ALLOGENE THERAPEUTICS; CO WILL BE REPRESENTED ON ALLOGENE’S BOARD Source text for Eikon: Further company coverage: